Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.

At the OCT DACH conference, experts shared how EU laws, digitalisation, and more, are impacting trials in the DACH region and ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

Intelligent Bio Solutions plans to file for 510(k) clearance with the US FDA in Q4 this year. Image credit: PRESSLAB / Shutterstock. US based company Intelligent Bio Solutions has released “strong ...

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

They say lightning rarely strikes twice but Kezar Life Sciences has suffered its second clinical blow in as many months.

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...

The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...